VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) today and set a price target ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures, after stocks surged to record highs following Donald Trump's presidential victory.The Dow Jones and S&P 500 ...

to President of Research and Development. Dr. Sethuraman has brought broad experience to the Company since its inception and has been invaluable in advancing ENTR-601-44 into the clinic. In November ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and welcome to the Vertex Inc. Third Quarter 2024 ...